Correction to: Antibody against TDP-43 phosphorylated at serine 369 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes

Manuela Neumann^{1,2} · Petra Frick¹ · Francesca Paron³ · Jonas Kosten¹ · Emanuele Buratti³ · Ian R. Mackenzie⁴

Published online: 3 November 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to: Acta Neuropathologica (2020) 140:645–658
<https://doi.org/10.1007/s00401-020-02207-w>

Due to a mistake with incorrect assignment of the originally planned amino acid residues 368–379 to the protein sequence of TDP-43 for antibody production by the contracted company, a peptide corresponding to amino acids 362–373 with a phosphorylated serin at 369 instead of a peptide corresponding to amino acids 368–379 with a phosphorylated serin at 375 was synthesized and used for antibody generation and purification.

Thus, the study in fact describes findings with a novel antibody against TDP-43 phosphorylated at serine 369 and not against TDP-43 phosphorylated at serine 375.

All presented results and conclusions of the study with the main finding of TDP-43 type-specific staining properties of this antibody are not affected.

1. The title should read as follows:

Antibody against TDP-43 phosphorylated at serine 369 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.

2. Throughout the text, figures and table 2 all references to pTDP-43^{S375} should actually refer to pTDP-43^{S369}.

3. The sentences in the “Methods” section should read as follows:

Generation of polyclonal pTDP-43^{S369} antibody

The rabbit polyclonal antibody against TDP-43 phosphorylated at serine 369 was produced by Biosense/Eurogentec using their custom polyclonal antibody cross-affinity purification service. Briefly, rabbits were immunized with a phosphopeptide corresponding to amino acid 362–373 of human TDP-43: ac-EPNQAFGS(p)GNNS-C-CONH₂. Phospho-specific antibodies were purified using affinity chromatography with modified and unmodified peptides.

The original article can be found online at <https://doi.org/10.1007/s00401-020-02207-w>.

✉ Manuela Neumann
manuela.neumann@dzne.de

¹ Molecular Neuropathology of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Tübingen, Otfried-Müllerstr. 23, 72072 Tübingen, Germany

² Department of Neuropathology, University Hospital of Tübingen, Tübingen, Germany

³ Department of Molecular Pathology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy

⁴ Department of Pathology, University of British Columbia and Vancouver General Hospital, Vancouver, Canada

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.